ARISTO — Aristo Bio-Tech and Lifescience Income Statement
0.000.00%
- IN₹932.67m
- IN₹1.13bn
- IN₹2.45bn
- 46
- 31
- 79
- 53
Annual income statement for Aristo Bio-Tech and Lifescience, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,012 | 1,672 | 1,660 | 2,179 | 2,451 |
Cost of Revenue | |||||
Gross Profit | 137 | 172 | 189 | 221 | 194 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,972 | 1,636 | 1,616 | 2,107 | 2,382 |
Operating Profit | 39.9 | 35.9 | 43.6 | 71.7 | 69.2 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 14 | 15 | 20.4 | 47.4 | 54.1 |
Provision for Income Taxes | |||||
Net Income After Taxes | 10.1 | 10.8 | 14.5 | 35.6 | 39 |
Net Income Before Extraordinary Items | |||||
Net Income | 10.1 | 10.8 | 14.5 | 35.6 | 39 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 10.1 | 10.8 | 14.5 | 35.6 | 39 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.48 | 1.58 | 2.11 | 5.23 | 5.72 |
Dividends per Share |